A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal Nimenrix® Vaccine When Given to Healthy Infants at 3 and 12 Months of Age
Sign Up to like & getrecommendations! Published in 2025 at "Infectious Diseases and Therapy"
DOI: 10.1007/s40121-024-01098-8
Abstract: Infants and young children typically have the highest age-related risk of invasive meningococcal disease. The immunogenicity and safety of a single primary dose and a booster of a meningococcal A/C/W/Y tetanus toxoid conjugate vaccine (MenACWY-TT;… read more here.
Keywords: age; month; nimenrix; booster ... See more keywords